Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Brown Capital Management LLC

Brown Capital Management LLC decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 53.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,510 shares of the medical research company’s stock after selling 18,661 shares during the period. Brown Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,089,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $29,000. Webster Bank N. A. acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at about $39,000. Versant Capital Management Inc increased its position in Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after buying an additional 326 shares in the last quarter. Finally, Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $32,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.9 %

EW stock opened at $69.54 on Thursday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $41.01 billion, a PE ratio of 10.03, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. The business’s 50-day simple moving average is $67.61 and its 200 day simple moving average is $75.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.59 EPS. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. The trade was a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,000 shares of company stock worth $2,657,000. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Barclays cut their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.